Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

By L. Wallentin, Richard C. Becker, A. Budaj, C. Cannon, H. Emanuelsson, C. Held, J. Horrow, S. Husted, S. James, H. Katus and 8 more. New England Journal of Medicine, 2009

6,318 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/e4e73dc127c3caf9bcb6e0d56ab97cac7c7123d3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

Citations in the corpus

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. (2010, methodology): “The clinical benefit of achieving ower levels of on-treatment platelet reactivity was suggested by he TRITON–TIMI 38 (Trial to Assess Improvement in herapeutic Outcomes by Optimizing Platelet Inhibition ith Prasugrel–Thrombolysis In Myocardial Infarction 38) 95) and the PLATO (Platelet Inhibition an”
2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, background): “PLATO Wallentin 2009 (139) 19717846 Determine whether ticagrelor is superior to clopidogrel for”
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. (2012, positive): “Clearly, after stenting for ACS, particularly STEMI, extended DAPT reduces the risk of stent thrombosis, reinfarction and cardiovascular mortality,(249) and more potent DAPT is associated with greater clinical benefits post-ACS of any type.(109,110,188) Pending the results of ongoing trials, a 9–12 ”
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. (2017, background): “prasugrel, ticagrelor, or clopidogrel), is recommended in patients with STEMI who are undergoing primary PCI (for up to 12 months).(186,187) Clopidogrel is recommended for 1 month in patients treated with fibrinolysis without subsequent PCI.”
2018 ESC/EACTS Guidelines on myocardial revascularization. (2019, neutral): “10.2 Prevention of contrast-induced nephropathy The risk of contrast-induced nephropathy (CIN) depends on patientrelated factors, such as CKD, diabetes mellitus, congestive HF, haemodynamic instability, reduced plasma volume, female sex, advanced age, anaemia, and periprocedural bleeding, as well as”
Atherosclerosis: current pathogenesis and therapeutic options (2011, background): “Platelet inhibition with aspirin has proved an enduring pillar for secondary prevention in patients with ACS, a benefit enhanced by other antiplatelet agents, such as clopidogrel, prasugrel or ticagrelo”